animal-models
(2)
Reza Rezaei Built a Career at the Handoff Between Science and Sales
A veterinarian and animal scientist learned to translate laboratory detail into commercial trust. After a decade climbing Cyagen's ranks, Reza Rezaei now leads the company from the junction of research, customers and scale.
Andrew Reaume
Andrew Reaume is the co-founder, President and CEO of Melior Discovery, an Exton, Pennsylvania preclinical contract research organization built around theraTRACE, a multiplexed in vivo phenotypic screening platform that runs a single drug candidate through a battery of animal disease models at once to uncover unexpected therapeutic uses. A geneticist by training with a Wharton MBA, he conceived the idea at Pfizer, left in 2005 to build it, and has since raised over $15 million in capital, closed more than $40 million in partnering deals, and pushed a repurposed compound, MLR-1023, into Phase 2 diabetes trials.